NXL

Nexalin Technology, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website nexalin.com
Employees(FY) 6
ISIN US65345B2016

Performance

+17.69%

+8.51%

+34.21%

+175.68%

+10.87%

YTD

+774.54%

Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.

Advanced Technical Analysis

Technical Analysis of NXL 2025-02-03

The stock exhibits a strong bullish sentiment, highlighted by a high Moving Average Score of 90 and a solid Technical Score of 83, indicating robust upward momentum. While the Oscillators Score of 60 suggests a neutral stance, the overall indicators point towards a favorable outlook for potential price appreciation.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NXL

Stock Rank

Recent News & Updates

2024-06-03 20:30
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th(Globenewswire)
2024-06-02 20:30
FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity Headset Device(Globenewswire)
2024-05-29 19:47
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday(Investorplace)
2024-05-21 20:30
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts(Globenewswire)
2024-05-12 22:54
NXL Stock Earnings: Nexalin Technology Reported Results for Q1 2024(Investorplace)
2024-05-08 20:30
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23(Globenewswire)
2024-04-24 22:44
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements(Globenewswire)
2024-04-09 20:30
Nexalin Technology CEO Provides Letter to Shareholders(Globenewswire)
2024-04-08 20:30
Nexalin Technology Accelerates Manufacturing of its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing(Globenewswire)
2024-04-04 01:00
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity , a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device(Globenewswire)
2024-04-03 23:05
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device(Newsdirect)
2024-04-01 20:30
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board(Globenewswire)
2024-03-27 20:30
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego(Globenewswire)
2024-03-13 20:30
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology(Globenewswire)
2024-03-12 20:30
Nexalin Technology Announces Poster Presentation at State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment(Globenewswire)
2024-03-05 19:30
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia(Globenewswire)
2024-02-07 19:30
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device(Globenewswire)
2024-01-22 19:30
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System(Globenewswire)
2024-01-10 19:30
Nexalin Technology Unveils Next-Generation HALO Clarity(Globenewswire)
2023-12-17 19:30
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression(Globenewswire)
2023-10-24 20:30
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter(Globenewswire)
2023-10-15 20:30
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures(Globenewswire)
2023-08-06 20:30
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms(Yahoo Finance)
2023-08-02 20:30
Nexalins CEO Mark White to be Interviewed Live on The Big Biz Show Today at 3PM Eastern Time(Yahoo Finance)
2023-07-25 20:30
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies(Yahoo Finance)
2023-07-09 20:30
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury(Yahoo Finance)
2023-05-31 20:30
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalins tACS Devices in the Asia Pacific Region(Yahoo Finance)
2023-03-29 18:33
Nexalin Technology Full Year 2022 Earnings: US$0.30 loss per share (vs US$1.43 loss in FY 2021)(Yahoo Finance)
2023-03-26 19:00
Nexalin Technology Provides 2022 Year-End Business Update(Yahoo Finance)
2023-01-23 19:30
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory(Yahoo Finance)

Page 2 of 3

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.